Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared…